10x Genomics (TXG) Preferred Stock Liabilities (2018 - 2019)

10x Genomics (TXG) posted Preferred Stock Liabilities of $243.2 million for Q2 2019, little changed sequentially from $243.2 million in Q1 2019.

10x Genomics (TXG) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

10x Genomics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $243.2 million in Q2 2019.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $243.2 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $243.2 million (changed N/A YoY) and the FY2018 annual result came in at $243.2 million, up 53.55% from the prior year.
Preferred Stock Liabilities steadied at $243.2 million in Q2 2019 per TXG's latest filing, from $243.2 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $243.2 million in Q4 2018 and troughed at $208.3 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn	-
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn	-
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn	-
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn	-
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn	-
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn	-
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn	-
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn	-
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn	-
10	Privia Health	2.78 Bn	2.42 Bn	-	-

Download Data